Un­der the gun, Ny­mox sparks an­oth­er ral­ly with a new batch of fol­low-up BPH da­ta

More than a year ago, Ny­mox Phar­ma­ceu­ti­cal man­aged to whip up a big ral­ly for its bat­tered stock $NYMX af­ter claim­ing an un­ex­pect­ed turn­around for its lead drug fexapotide for treat­ing an en­larged prostate. A pair of late-stage fail­ures — which shred­ded its stock — had been over­come with pos­i­tive da­ta from an ex­ten­sion of the tri­al, ex­ecs said.

The next step, com­pa­ny CEO Paul Aver­back as­sured in­vestors, would be to trek to reg­u­la­tors for a dis­cus­sion about fil­ing for an ap­proval on the drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER